Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

TYL vs WST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

WST Captures Overall Composite Edge (39.8 SELL vs 40.4 SELL), While TYL Leads 4–2 on Growth & Valuation Pillars

WST Overall Winner 6-Pillar Tally: TYL 4 – 2 WST Matrix Metrics: TYL 2 – 7 WST

As of Nov 17, 2026, West Pharmaceutical Services, Inc. (WST) captures the overall head-to-head institutional edge over Tyler Technologies, Inc. (TYL) on higher Unified Composite conviction (39.8/100 SELL vs. 40.4/100 SELL) after splitting the core matrix 7–2 (led by Growth & Scale, Profitability & Quality), while TYL wins 4–2 across the 6-pillar growth and valuation breakdown. TYL trades at $414.03 (27.4x Forward P/E, 15.7% operating margin) versus WST at $413.28 (40.2x Forward P/E, 22.9% operating margin).

  • Composite vs. Pillar Nuance: While TYL currently prints a higher short-term Unified Composite Score (40.4/100 SELL vs. WST 39.8/100 SELL), WST captures the overall institutional head-to-head verdict (7–2 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (22.9% vs. 15.7% operating margin) and revenue trajectory (+8.7% vs. +8.7% YoY).
  • Defensive Composite Rating Caution: Although WST compares more favorably head-to-head, both TYL (40.4/100 SELL) and WST (39.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TYL vs WST
TYL NYSE
Tyler Technologies, Inc.
Services-Prepackaged Software
$414.03
-2.81% 1D
Market Cap $16.9B
TTM Revenue $2.48B
Forward P/E 27.4x
Beta / 30D Vol -0.39β · 42% Vol
Unified Composite Score
40.4 / 100 SELL
Tech 19.0 Fund 34.0 Flow 68.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.2% over 20 days), RSI 63
RSI-14: 62.6 · SMA20: $404.55 · SMA50: $365.11
WST NYSE Head-to-Head Winner
West Pharmaceutical Services, Inc.
Surgical & Medical Instruments & Apparatus
$413.28
-1.08% 1D
Market Cap $29.0B
TTM Revenue $3.40B
Forward P/E 40.2x
Beta / 30D Vol 0.46β · 24% Vol
Unified Composite Score
39.8 / 100 SELL
Tech 26.0 Fund 34.0 Flow 54.0 Mom 1.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.6% over 20 days), RSI 64
RSI-14: 63.6 · SMA20: $406.03 · SMA50: $383.28

6-Pillar Scorecard Institutional Category Breakdown (TYL 4 – 2 WST)

Columns: Metric · TYL · WST
1. Valuation Multiples TYL
Forward P/E 27.4x 40.2x
Trailing P/E 52.9x 46.7x
PEG Ratio 1.54x 3.03x
EV / Revenue 7.1x 8.5x
2. Growth & Scale WST
Revenue Growth (YoY) +8.7% +8.7%
Earnings Growth (YoY) +20.7% +57.3%
TTM Revenue (USD) $2.48B $3.40B
Market Cap $16.9B $29.0B
3. Profitability & Quality WST
Gross Margin 47.7% 37.6%
Operating Margin 15.7% 22.9%
Net Profit Margin 13.5% 18.8%
Return on Equity (ROE) 10.5% 21.2%
4. Balance Sheet & Cash Flow TYL
Cash Generation (TTM) $735M $453M
Cash Flow Margin 29.6% 13.3%
Net Cash / Leverage $667M Net Debt (0.52x D/E) $159M Net Cash
Dividend Yield None (0.00%) 0.21%
5. Options & Positioning TYL
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 39.2% (22nd %ile) 26.0% (13th %ile)
Put/Call OI Skew 0.05x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat TYL
OpEx & R&D Intensity 32.0% of Rev ($794M) 14.7% of Rev ($499M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Software - Application Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TYL (2) vs WST (7)
Institutional Metric TYL WST Criterion Row Edge
Market Capitalization
Scale
$16.9B $29.0B Larger Scale WST
Trailing P/E Ratio
Valuation
52.9x 46.7x Lower Multiple WST
Forward P/E Ratio
Valuation
27.4x 40.2x Lower Multiple TYL
Revenue Growth (YoY)
Growth
+8.7% +8.7% Higher Growth Tie
Operating Margin (TTM)
Profitability
15.7% 22.9% Higher Margin WST
Net Profit Margin
Profitability
13.5% 18.8% Higher Margin WST
Return on Equity (ROE)
Capital Efficiency
10.5% 21.2% Higher ROE WST
52-Week Range Position
Momentum
68% ($271–$482) 88% ($224–$438) Stronger Trend WST
Beta / 30D Volatility
Risk Regime
-0.39β · 42% Vol 0.46β · 24% Vol Lower Realized Risk WST
Unified Institutional Score
Composite Signal
40.4 / 100 (SELL) 39.8 / 100 (SELL) Higher Composite TYL
Trailing 12M Revenue (USD)
Operating Scale
$2.48B $3.40B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
47.7% 37.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.54x PEG · 7.1x EV/Rev 3.03x PEG · 8.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$735M ($667M Net Debt (0.52x D/E)) $453M ($159M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TYL +7.33 pp
TYL: +14.98% · WST: +7.65%
3M Horizon TYL +2.21 pp
TYL: +19.36% · WST: +17.15%
6M Horizon WST +7.69 pp
TYL: +28.29% · WST: +35.98%
1Y Horizon WST +69.59 pp
TYL: -11.46% · WST: +58.13%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period TYL Revenue WST Revenue TYL Op. Margin WST Op. Margin Margin Leader
FY2018 $940M $1.72B 16.3% 14.0% TYL
FY2019 $1.09B $1.84B 14.4% 16.1% WST
FY2020 $1.12B $2.15B 15.5% 19.0% WST
FY2021 $1.59B $2.83B 11.4% 26.6% WST
FY2022 $1.85B $2.89B 11.6% 25.4% WST
FY2023 $1.95B $2.95B 11.2% 22.9% WST
FY2024 $2.14B $2.89B 14.0% 19.7% WST
FY2025 $2.33B $3.07B 15.3% 19.0% WST

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TYL BREAKOUT
52d in phase · OBV ACCUMULATION
Current IV 39.2%
IV Percentile 22nd %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact TYL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
WST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 26.0%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact WST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $417.79 · IV 36.4%

TYL Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($41,779)

Compare $41,779 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 36.4% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $420 / $440 Bull Call Spread

Buy 1x $420C · Sell 1x $440C · 31d

Net Entry $1,050 Debit
T+5d @ +5% Move +$280 (+27%)
Max Risk / Buffer $1,050 Capped
5d Edge & Liquidity 0.7x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Dec 18 $380 / $350 Bull Put Spread

Sell 1x $380P · Buy 1x $350P · 31d

Net Entry $358 Credit
Max Credit / Yield +$358 (+13.6% RoM)
Max Risk / Buffer -9.9% Cushion ($2,642 Mgn)
5d Edge & Liquidity 81% PoP · Liq C
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $380P / $420-$460C Seagull

Sell 1x $380P · Buy 1x $420/$460C · 31d

Net Entry $1,105 Debit
T+5d @ +5% Move +$933 (+14.9% RoM)
Max Risk / Buffer -9.0% Put Cushion ($6,247 Mgn)
5d Edge & Liquidity 0.7x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TYL Moat Profile Scale & Operating Efficiency Moat
Software - Application Operator
Competes within the Software - Application value chain with $16.9B market capitalization and 15.7% operating margin.
OpEx & R&D Reinvestment 32.0% of Rev ($794M)
90D Engineering Disclosures 0 Published
WST Moat Profile Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $29.0B market capitalization and 22.9% operating margin.
OpEx & R&D Reinvestment 14.7% of Rev ($499M)
90D Engineering Disclosures 0 Published

Investor FAQ TYL vs WST Key Questions & Quantitative Answers

As of Nov 17, 2026, West Pharmaceutical Services, Inc. (WST) captures the overall head-to-head institutional edge over Tyler Technologies, Inc. (TYL) on higher Unified Composite conviction (39.8/100 SELL vs. 40.4/100 SELL) after splitting the core matrix 7–2 (led by Growth & Scale, Profitability & Quality), while TYL wins 4–2 across the 6-pillar growth and valuation breakdown. TYL trades at $414.03 (27.4x Forward P/E, 15.7% operating margin) versus WST at $413.28 (40.2x Forward P/E, 22.9% operating margin). Composite vs. Pillar Nuance: While TYL currently prints a higher short-term Unified Composite Score (40.4/100 SELL vs. WST 39.8/100 SELL), WST captures the overall institutional head-to-head verdict (7–2 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (22.9% vs. 15.7% operating margin) and revenue trajectory (+8.7% vs. +8.7% YoY). Defensive Composite Rating Caution: Although WST compares more favorably head-to-head, both TYL (40.4/100 SELL) and WST (39.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

WST leads the Growth & Scale pillar: TYL posts +8.7% YoY revenue growth and +20.7% YoY earnings growth on $2.48B TTM revenue (47.7% gross margin, 15.7% operating margin), compared with WST at +8.7% YoY revenue growth and +57.3% YoY earnings growth on $3.40B TTM revenue (37.6% gross margin, 22.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), TYL cumulative revenue shifted +147.9% while WST shifted +78.5%. In operating R&D and SG&A reinvestment, TYL deploys 32.0% of Rev ($794M) (0 90-day corporate R&D disclosures) versus 14.7% of Rev ($499M) (0 disclosures) for WST.

TYL screens cheaper on headline valuation multiples. TYL trades at 27.4x Forward P/E, 52.9x Trailing P/E, 1.54x PEG, and 7.1x EV/Revenue (29.6% FCF margin), whereas WST trades at 40.2x Forward P/E, 46.7x Trailing P/E, 3.03x PEG, and 8.5x EV/Revenue (13.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TYL (10.5% ROE) versus WST (21.2% ROE) capital efficiency.

In options market volatility and institutional positioning, TYL carries 39.2% implied volatility (22nd %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (-0.39β · 42% Vol realized risk). By comparison, WST carries 26.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 24% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.